QHP Capital

Jared J. Greer joins the QHP Team as Director of Portfolio Company Operations! Jared brings expertise in business optimization and leadership development, with a background in adult education, management consulting, and high-performance coaching—plus he’s a 6x Ironman finisher. 🏅 Background - Founder of an executive coaching and optimization practice - Leadership consultant at CEB (now Gartner), advising Ford, Mars, and AIG - Expert in operational efficiency, management systems, and value creation In this new role, Jared will leverage his experience to enhance operational efficiency, drive value creation, and help our portfolio achieve their strategic goals. We’re excited to have him on board! === QHP Capital A private equity firm specializing in life sciences, dedicated to investing in innovative companies that drive advancement across the healthcare value chain. #PrivateEquity #LifeSciences #MergersAcquisitionsDivertitures #Team

We are excited to announce the promotion of Christine Fornes to Chief Compliance Officer! Christine has been an invaluable asset to our team, consistently demonstrating her expertise and commitment to excellence. Her strategic insight and deep understanding of regulatory landscapes have been instrumental in our growth and success. With increasing regulatory scrutiny in private markets, Christine’s leadership strengthens our robust compliance framework. This empowers stakeholders to invest with confidence, knowing their interests are protected and our practices exceed industry standards.   Congrats, Christine! === QHP Capital A private equity firm specializing in life sciences, dedicated to investing in innovative companies that drive advancement across the healthcare value chain. #privateequity #lifesciences #mergersacquisitionsdivertitures #team

🔍 There are a variety of programs and strategies that promote broader market access and help patients access therapies at the right time and appropriate economics: - Engaging regulators early  - Aligning pricing with clinical outcomes through risk-sharing - Leveraging real-world data for reimbursement - Demonstrating cost-effectiveness - Improving patient affordability  - Driving the adoption of new therapies through targeted research and advocacy Learn more about market access challenges by watching the final video in our 3-part series: ------------------------ The opinions expressed herein are those of QHP Capital, L.P. (“QHP Capital”) and are subject to change without notice. This is not an offer to buy or sell a security. Such an offer will made by a confidential private placement memorandum. QHP Capital is a registered investment adviser with the U.S. Securities and Exchange Commission. Registration does not imply a certain level of skill or training.   More information about QHP Capital can be found in our ADV Part 2, which is available upon request. #lifesciences #privateequity #mergersacquisitionsdivestitures #alternativeinvestments

CoreRx, Societal CDMO, and Bend Bioscience have united under one brand: Bend Bioscience! The decision to adopt the Bend Bioscience name reflects the company's commitment to innovation, technical excellence, and unmatched customer service. "Bend Bioscience was chosen as the unified brand because it encapsulates the scientific excellence and innovative spirit that all three companies represent," said Owen Murray, CEO of Bend Bioscience. "This merger is not just about combining resources; it's about building on the strengths of CoreRx's advanced formulation development, Societal CDMO's respected manufacturing capabilities in the area of modified release, and Bend Bioscience's leadership in scientific research and technology." As a unified organization, Bend is poised to leverage its combined expertise and end-to-end scale, enhance operational efficiencies, and deliver comprehensive, high-quality services that help bring life-saving therapies to market faster and more efficiently. Check out the full press release in the comments below. === QHP Capital    A private equity firm specializing in life sciences, dedicated to investing in innovative companies that drive advancement across the healthcare value chain.   #privateequity #mergersandaquisitionsanddivestitures #lifesciences

After 35+ years of navigating career transitions, I’ve learned that success comes down to these five essentials: - Passion - It’s what drives you through the highs and lows. Without it, the journey becomes a grind. - Contribution - Make an impact from day-one. Your expertise should immediately fuel the organization’s growth. - Culture - If your culture and the company’s culture don’t align, success is hard to sustain. It’s a two-way street; both sides need to connect for it to work. - Growth - Every role is a chance to learn and evolve. It’s about ongoing development, not just reaching a destination. - Compensation - Get the first four right, and this will follow naturally. These lessons have shaped how I approach every opportunity and are key to “Accelerating Growth” within an organization. 👉 Watch the full video below. === QHP Capital A private equity firm specializing in life sciences, dedicated to investing in innovative companies that drive advancement across the healthcare value chain. #privateequity #mergersandaquisitionsanddivestitures #alternativeinvestments

The reviews are pouring in! In just 3 months, "Accelerating Growth" has sparked conversations and inspired CEOs and management teams worldwide, earning its place as a #1 New Release in Organizational Change and Business Planning. 🎉 Have you grabbed your copy yet? Don’t miss out—get yours today and don’t forget to leave a review 🔗 https://lnkd.in/eBgKqnSF === QHP Capital A private equity firm specializing in life sciences, dedicated to investing in innovative companies that drive advancement across the healthcare value chain. #privateequity #mergersandaquisitionsanddivestitures #alternativeinvestments

Bringing new therapies to market requires more than innovation—it's about navigating challenges that can delay or prevent patients from receiving the treatments they need. These key challenges include: Regulatory Hurdles: Navigating approval processes in different countries, like the FDA and EMA, requires extensive data on safety and efficacy. Pricing & Reimbursement: High drug prices can lead to coverage denials, limiting patient access.   Health Technology Assessments (HTAs): Negative assessments can block reimbursement and reduce availability. Market Exclusivity: Post-exclusivity, generic competition can drive down prices and market share. Logistics & Distribution: Ensuring a reliable supply chain, especially for biologics, remains challenging. At QHP, we partner with industry leaders to help develop and scale solutions that address critical challenges across the entire pharmaceutical services value chain. Watch the second video in our 3-part series on market access challenges below:  —----- The opinions expressed herein are those of QHP Capital, L.P. (“QHP Capital”) and are subject to change without notice. This is not an offer to buy or sell a security. Such an offer will made by a confidential private placement memorandum. QHP Capital is a registered investment adviser with the U.S. Securities and Exchange Commission. Registration does not imply a certain level of skill or training. #lifesciences #privateequity #mergersacquisitionsdivestitures #alternativeinvestments

It’s never too late to implement transformative solutions in your organization. Accelerating Growth offers the blueprint. When I wrote Accelerating Growth, my goal was to create a practical guide for CEOs and management teams — a hands-on resource for immediate action, not just another business strategy book. The response has been incredible, with companies from all over the world adopting it’s strategies. If you've read the book, I’d love to hear how The Management System has influenced your organization and made a difference. Your feedback is invaluable—please consider leaving an Amazon review (link in comments). === QHP Capital A private equity firm specializing in life sciences, dedicated to investing in innovative companies that drive advancement across the healthcare value chain. #privateequity #lifesciences #mergersacquisitionsdivertitures

Ricky Turner has joined the QHP Team as VP of Value Creation! With 20+ years of executive leadership experience, Ricky is responsible for maximizing talent within our portfolio and helping our companies build high-performing leadership teams. Ricky’s Experience: - Leadership roles with Fortune 100 companies: Meta, Nike, Whirlpool Corporation  - Board advisor to several fast-growing companies - Sought-after keynote speaker and podcast interviewee We’re excited to have Ricky on board as we continue investing in innovative life science companies driving healthcare investments. === QHP Capital A private equity firm specializing in life sciences, dedicated to investing in innovative companies that drive advancement across the healthcare value chain. #privateequity #lifesciences #mergersacquisitionsdivertitures #team

ASC’s Mission: Create affordable, off-the-shelf cell products to save lives For 15+ years, Ruby, CEO and Co-founder of Applied StemCell, has driven groundbreaking advancements in gene editing and cell therapy, transforming patient access to life-changing treatments. Traditional cell therapy: - $500,000 per treatment  - 2-3 treatments needed, months to produce - Patients can only use their own cells “Not only is Ruby an accomplished scientist and executive but she brings a tremendous commitment to ASC's mission of advancing gene-editing and stem cell innovation for biomedical research and gene and cell therapy."- Matt Jenkins, Partner at QHP #lifesciences #mergersacquisitionsdivestitures #privateequity #cellandgenetherapy